Information  X 
Enter a valid email address

Omega Diagnostics Gp (ODX)


Monday 10 January, 2022

Omega Diagnostics Gp

Confirmation of detection of Omicron variant

RNS Number : 9725X
Omega Diagnostics Group PLC
10 January 2022


("Omega" or the "Company" or the "Group")


Confirmation of detection of Omicron variant

VISITECT® COVID-19 antigen test performs with the same high accuracy on the Omicron variant


Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, notes concerns regarding the ability of certain lateral flow tests to detect the Omicron variant with the same sensitivity for lower viral loads.


Further to the announcement on 14 December 2021 , the Company's technology partner Mologic Ltd ("Mologic") has today re-confirmed that the Mologic Covios® Ag lateral flow test, performs with the same high accuracy on the Omicron variant as it does with existing known variants.


Mologic's studies are ongoing to determine the absolute performance of the test across the use case settings and in laboratory environments to produce a comprehensive analysis of the detection of Omicron. No data exists to suggest there is an issue, be that in silico or in trials.


This is the same test that is manufactured and sold for professional use by Omega as the VISITECT® COVID-19 antigen test.




Omega Diagnostics Group PLC

Colin King, Chief Executive Officer 

via Walbrook PR

Chris Lea, Chief Financial Officer

finnCap Ltd  

Tel: 020 7220 0500

Geoff Nash/Edward Whiley (Corporate Finance)

Alice Lane/ Charlotte Sutcliffe (ECM)

Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]

Paul McManus

Mob: 07980 541 893

Lianne Applegarth

Mob: 07584 391 303

Sam Allen

Mob: 07502 558 258



About Omega Diagnostics Group PLC

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 75 countries and specialise in the areas of health and nutrition and global health.


This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t